A literature review and evidence-based evaluation of the Dutch national immunisation schedule yield possibilities for improvements.

Autor:	Pluijmaekers AJM; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., Steens A; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., Houweling H; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., Rots NY; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., Benschop KSM; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., van Binnendijk RS; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., Bodewes R; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., Brouwer JGM; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., Buisman A; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., Duizer E; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., van Els CACM; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands.; Faculty of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, The Netherlands., Hament JM; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., den Hartog G; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands.; Laboratory of Medical Immunology, Radboud UMC, Nijmegen, The Netherlands., Kaaijk P; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., Kerkhof K; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., King AJ; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., van der Klis FRM; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., Korthals Altes H; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., van der Maas NAT; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., van Meijeren DL; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., Middeldorp M; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., Rijnbende-Geraerts SD; Public Health, Municipality of Utrecht, The Netherlands., Sanders EAM; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands.; Department of Paediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital and University Medical Centre Utrecht, The Netherlands., Veldhuijzen IK; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., Vlaanderen E; Municipal Health Service of Hollands Noorden, The Netherlands., Voordouw ACG; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., Vos ERA; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., de Wit J; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., Woudenberg T; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., van Vliet JA; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands., de Melker HE; Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), The Netherlands.
Jazyk:	angličtina
Zdroj:	Vaccine: X [Vaccine X] 2024 Sep 26; Vol. 20, pp. 100556. Date of Electronic Publication: 2024 Sep 26 (Print Publication: 2024).
DOI:	10.1016/j.jvacx.2024.100556
Abstrakt:	National Immunisation Programmes (NIPs) develop historically. Its performance (disease incidences, vaccination coverage) is monitored. Reviewing the schedule as a whole could inform on further optimisation of the programme, i.e., providing maximal protection with the lowest number of doses. We systematically evaluated the performance and strategies of the Dutch pathogen-specific NIP schedules through literature review, assessment of surveillance data and expert opinions. Pathogen-specific vaccinations were categorised according to their strategy of protection: I) elimination or eradication, II) herd immunity or III) 'only' individual protection. The schedule of each vaccine-component was evaluated based on fixed criteria: 1. Is the achieved protection adequate? 2. Is the intended protection achieved? 3. Does the programme include too many or too few doses? 4. Is the timing optimal or acceptable? and 5. Are there drawbacks of the NIP for (part of) the population? Identified issues were explored using surveillance data and literature. Using fixed criteria facilitated comparison between pathogens and revealed opportunities to optimise the Dutch NIP by: i. Reducing the number of polio and tetanus vaccinations; ii. prolonging the interval between diphtheria, pertussis, tetanus, polio, hepatitis B, and Hib vaccine doses for improved effectiveness; iii. Expedite the second measles vaccination from 9 to 2-4 years of age to offer unvaccinated children and primary vaccine failures an earlier chance to be protected; and iv. Delaying the second mumps vaccination to enhance protection in adolescents/young adults. No schedule adaptations were deemed necessary for the vaccines against HPV, rubella, pneumococcal disease, and meningococcal disease. Based on this evaluation the NITAG advised to move the DTaP-IPV-HBV-Hib-booster from age 11 to 12 months, the second MMR-dose from 9 to 2-4 years, replace the Tdap-IPV at 4 years with a Tdap at 5-6 years and move the dt-IPV from 9 to 14 years. Implementation of these changes is planned for 2025. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2024 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu